Ionis Pharmaceuticals, Inc. Common Stock
$44.44
-$2.31 (-4.94%)
$44.27Day Range$46.75
Key Statistics
Market Cap
$7.39B
Shares Outstanding
166.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 17, 1991
Round Lot
100
Locale
US
Trading Data
Day Open
$46.75
Day High
$46.75
Day Low
$44.27
Volume
7.37M
VWAP
$44.68
Prev Close
$46.75
Transactions
--
Acc. Volume
--
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
PHARMACEUTICAL PREPARATIONSSIC 28341,402 employees2855 GAZELLE COURT, CARLSBAD, CA, 92010(760) 931-9200IPO May 17, 1991US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000874015
- Composite FIGI
- BBG000JH6683
- Share Class FIGI
- BBG001SB7RD1
- Ticker Root
- IONS
- SIC Code
- 2834
About Ionis Pharmaceuticals, Inc. Common Stock (IONS) Stock
Ionis Pharmaceuticals, Inc. Common Stock (IONS) closed the 2026-09-18 session at $44.44, down 4.94% versus the previous close (-2.31). The stock opened at $46.75 and traded between $44.27 and $46.75 during that session. Session trading volume was 7.4M shares. The volume-weighted average price (VWAP) is $44.68.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Ionis Pharmaceuticals, Inc. Common Stock has a market capitalization of $7.39 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IONS is listed on the XNAS exchange. The company employs approximately 1,402 people. Ionis Pharmaceuticals, Inc. Common Stock is headquartered in CARLSBAD, CA. The recorded listing date is 1991-05-17.
On this page you can find market IONS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.